Shares of Harrow Inc (HROW, Financial) surged 3.26% in mid-day trading on Oct 2. The stock reached an intraday high of $46.10, before settling at $45.90, up from its previous close of $44.45. This places HROW 3.47% below its 52-week high of $47.55 and 503.95% above its 52-week low of $7.60. Trading volume was 127,229 shares, 19.9% of the average daily volume of 640,221. Wall Street Analysts Forecast Based on the one-year price targets offered by 4 analysts, the average target price for Harrow Inc (HROW, Fin ...

Financial Data and Key Metrics Changes - Harrow achieved record quarterly revenue of $48.9 million, representing a 46% increase year-over-year and a 42% increase quarter-over-quarter [5][6] - The company expects 2024 revenue to exceed $180 million, excluding contributions from TRIESENCE [6][12] Business Line Data and Key Metrics Changes - The Anterior Segment business saw revenue increase by over 40% compared to the first quarter of 2024 [5] - ImprimisRx compounding subsidiary achieved its highest quarterly revenue in history [5] - Branded revenue is now ahead of compounded revenue, positively impacting margins [6] Market Data and Key Metrics Changes - IHEEZO unit volumes nearly doubled, up about 98% from the previous quarter, with 24 supply agreements signed with strategic retina practice accounts [7] - VEVYE prescriptions increased by 212% from the first quarter of 2024, with a total of 3,000 prescribers [8][9] Company Strategy and Development Direction - The company aims to become North America's leading ophthalmic pharmaceutical company, focusing on expanding the VEVYE salesforce and opening new territories [12][11] - Harrow is actively pursuing Medicare coverage for VEVYE, with expectations for coverage to be in place by early 2025 [14][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational momentum and growth potential for the second half of 2024, particularly with the relaunch of TRIESENCE [6][12] - Positive feedback from physicians regarding VEVYE's effectiveness and tolerability was highlighted, indicating strong market demand [10][12] Other Important Information - The company has a strong market access strategy, with VEVYE currently exceeding internal goals, covering over 166 million lives [9] - The company is focused on maintaining profitability while expanding its market presence and product offerings [51] Q&A Session Summary Question: Can you provide commentary on Medicare coverage for VEVYE? - The company is in the process of attaining Medicare coverage, which is expected to take 18 to 24 months from the product launch [14] Question: What is the size and scope of the VEVYE sales force? - The VEVYE sales force currently covers only 36 out of 59 markets, with plans to expand coverage in the coming quarters [15][16] Question: Can you discuss the reorder activity for IHEEZO? - The reorder rate for IHEEZO is currently at 87%, indicating strong interest from physicians [49] Question: What is driving the success in the Medicaid market for VEVYE? - The market access team has been successful in securing Medicaid coverage with zero co-pay for patients in large markets like Texas and California [23][51] Question: What is the expected market opportunity for IHEEZO and VEVYE? - The market opportunity for IHEEZO is significant, with over 17 million annual use cases in the US, while VEVYE targets a large population suffering from moderate to severe dry eye disease [56]

6 HARROW® Your patients. Our purpose. Investor Presentation | August 2024 Safe Harbor This presentation contains express "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectat ...

Harrow (HROW) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 48%. A quarter ago, it was expected that this pharmaceutical and drug compounding company would post a loss of $0.25 per share when it actually produced a loss of $0.28, delivering a surprise of -12%. Over the last four quarters, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name on exchange on which registered Common Stock, $0.001 par value per share HROW The Nasdaq Stock Market LLC 8.625% Senior Notes due 2026 HROWL The Nasdaq Stock Market LLC 11.875% Senior Notes due 2027 HROWM The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REP ...

EXHIBIT 99.1 Harrow Announces Second Quarter 2024 Financial Results Second Quarter 2024 and Recent Selected Highlights: ● Record revenues of $48.9 million ● GAAP net loss of $(6.5) million ● Adjusted EBITDA of $8.8 million ● Cash and cash equivalents of $71.0 million as of June 30, 2024 ● IHEEZO® customer unit demand volume increased by 98% from the first quarter of 2024 ● IHEEZO supply agreements total 24 agreements to date in 2024, including a recent win with the largest and highest volume U.S. retina pra ...

So, the price trend in HROW may not reverse anytime soon. In addition to HROW, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria. This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market. However, keep ...

Harrow (HROW) shares soared 12.9% in the last trading session to close at $19.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.5% gain over the past four weeks. This pharmaceutical and drug compounding company is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of -1150%. Revenues are expected to be $42.78 million, up 27.8% from the year-ago quarter. For Harr ...

| 17 | Investor Presentation | May 2024 • Steroids, NSAIDs, and Anti-inflammatories • an OTC preservative-free lubricant • an Antihistamine, and Antibiotics cyclosporine ophtha emulsion 0.1% "We know steroids effectively treat inflammation in DED. FLAREX is further differentiated from other steroids by increasing MUC1, MUC4, MUC16, and MUC19 gene expression in the conjunctival and corneal epithelial cells. Mucin is a critical component of DED in providing protection and binding the tear film to the ocular s ...

Harrow, Inc. (NASDAQ:HROW) Q1 2024 Earnings Call Transcript May 14, 2024 8:00 AM ET Company Participants Jamie Webb - Director of Communications and IR Mark L. Baum - CEO Andrew Boll - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Chase Knickerbocker - Craig-Hallum Brooks O'Neil - Lake Street Capital Operator Good day, everyone, and welcome to the Harrow, Inc. First Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After toda ...